ARK Invest's position in PRME, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 10,039,824 | $39.1M | 1.98% | #18 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-11 | ARKG | Buy | Added | 1,744,714 | $7.5M |
| 2026-07-22 | ARKG | Buy | Added | 206,310 | $637K |
| 2026-07-21 | ARKG | Buy | Added | 76,393 | $238K |
| 2026-07-20 | ARKG | Buy | Added | 491,418 | $1.5M |
| 2026-07-17 | ARKG | Buy | Added | 81,580 | $255K |
| 2026-07-16 | ARKG | Buy | Added | 424,438 | $1.4M |
| 2026-07-15 | ARKG | Buy | Added | 54,881 | $192K |
| 2026-07-14 | ARKG | Buy | Added | 88,796 | $308K |
| 2026-07-13 | ARKG | Buy | Added | 246,729 | $867K |
| 2026-07-10 | ARKG | Buy | Added | 293,106 | $1.1M |
| 2026-07-09 | ARKG | Buy | Added | 544,385 | $2.3M |
| 2026-07-07 | ARKG | Buy | Added | 206,193 | $823K |
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in…
See PRME's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open PRME on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.